145 related articles for article (PubMed ID: 17210865)
1. BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?
Dunleavy K; Davis RE; Landgren O; Staudt LM; Wilson WH
Blood; 2007 Jan; 109(2):843-4; discussion 844-5. PubMed ID: 17210865
[No Abstract] [Full Text] [Related]
2. Immunochemotherapy is the standard of care in elderly patients with diffuse large B-cell lymphoma.
Coiffier B; Salles G
Blood; 2004 Sep; 104(5):1584-5; author reply 1585-6. PubMed ID: 15317734
[No Abstract] [Full Text] [Related]
3. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.
Wilson KS; Sehn LH; Berry B; Chhanabhai M; Fitzgerald CA; Gill KK; Klasa R; Skinnider B; Sutherland J; Connors JM; Gascoyne RD
Leuk Lymphoma; 2007 Jun; 48(6):1102-9. PubMed ID: 17577773
[TBL] [Abstract][Full Text] [Related]
4. CHOP plus rituximab--balancing facts and opinion.
Cheson BD
N Engl J Med; 2002 Jan; 346(4):280-2. PubMed ID: 11807154
[No Abstract] [Full Text] [Related]
5. Fulminant B hepatitis in a surface antigen and hepatitis B DNA-negative patient with diffuse large B-cell lymphoma after CHOP chemotherapy plus rituximab.
Yamagata M; Murohisa T; Tsuchida K; Okamoto Y; Tsunoda S; Nakamura M; Kusano K; Majima Y; Kuniyoshi T; Iijima M; Sugaya H; Hiraishi H
Leuk Lymphoma; 2007 Feb; 48(2):431-3. PubMed ID: 17325912
[No Abstract] [Full Text] [Related]
6. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
Akyurek N; Uner A; Benekli M; Barista I
Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphism at
Bashash M; Connors JM; Gascoyne RD; Meissner B; Schuetz JM; Leach S; Slack GW; Berry BR; Hu H; Sehn LH; Brooks-Wilson AR; Spinelli JJ
Haematologica; 2017 May; 102(5):e199-e202. PubMed ID: 28154089
[No Abstract] [Full Text] [Related]
8. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
9. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.
Mitroviç Z; Aurer I; Radman I; Ajdukoviç R; Sertiç J; Labar B
Haematologica; 2007 Jul; 92(7):998-9. PubMed ID: 17606457
[TBL] [Abstract][Full Text] [Related]
10. Intra-vascular large B-cell lymphoma revealed by a nephrotic syndrome: a one year remission induced by a high frequency CHOP and rituximab.
Girard T; Nochy D; Montravers F; Der Sahakian G; Fior R; Galanaud P; Boué F
Leuk Lymphoma; 2004 Aug; 45(8):1703-5. PubMed ID: 15370230
[TBL] [Abstract][Full Text] [Related]
11. [Primary diffuse large B-cell lymphoma in uterine corpus: report of a case].
Dong W; Cao L; Wang DS
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):270-2. PubMed ID: 21616007
[No Abstract] [Full Text] [Related]
12. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study.
Jerkeman M; Aman P; Cavallin-Stahl E; Torlakovic E; Akerman M; Mitelman F; Fioretos T
Int J Oncol; 2002 Jan; 20(1):161-5. PubMed ID: 11743658
[TBL] [Abstract][Full Text] [Related]
13. [Significance and application of c-myc in diffuse large B-cell lymphoma].
Huang WT; Lü N; Guo L
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):638-40. PubMed ID: 24314257
[No Abstract] [Full Text] [Related]
14. Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.
Pfreundschuh M
J Clin Oncol; 2012 Oct; 30(28):3433-5. PubMed ID: 22949148
[No Abstract] [Full Text] [Related]
15. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
George A; Tam CS; Seymour JF
Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
[No Abstract] [Full Text] [Related]
16. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
Horn H; Ziepert M; Becher C; Barth TF; Bernd HW; Feller AC; Klapper W; Hummel M; Stein H; Hansmann ML; Schmelter C; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Siebert R; Loeffler M; Rosenwald A; Ott G;
Blood; 2013 Mar; 121(12):2253-63. PubMed ID: 23335369
[TBL] [Abstract][Full Text] [Related]
17. TP53 mutations and rituximab-CHOP.
Gisselbrecht C
Blood; 2012 Nov; 120(19):3867-9. PubMed ID: 23144158
[No Abstract] [Full Text] [Related]
18. Diffuse large B-cell lymphoma.
Friedberg JW; Fisher RI
Hematol Oncol Clin North Am; 2008 Oct; 22(5):941-52, ix. PubMed ID: 18954744
[TBL] [Abstract][Full Text] [Related]
19. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
[TBL] [Abstract][Full Text] [Related]
20. CD30, another useful predictor of survival in DLBCL?
Chan WC
Blood; 2013 Apr; 121(14):2582-3. PubMed ID: 23557969
[No Abstract] [Full Text] [Related]
[Next] [New Search]
